{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:03:42Z","timestamp":1790679822193,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T00:00:00Z","timestamp":1484092800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s40263-016-0404-x","type":"journal-article","created":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T02:28:42Z","timestamp":1484101722000},"page":"245-251","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Benzodiazepine Use and Risk of Developing Alzheimer\u2019s Disease: A Case-Control Study Based on Swiss Claims Data"],"prefix":"10.1007","volume":"31","author":[{"given":"Fabienne A.","family":"Bi\u00e9try","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena M.","family":"Pfeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schwenkglenks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph R.","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,11]]},"reference":[{"key":"404_CR1","unstructured":"Schweizerische Alzheimervereinigung. Priorit\u00e4t Demenz-116000 Menschen mit Demenz in der Schweiz. alzheimer. 2014."},{"issue":"3","key":"404_CR2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrneurol.2011.2","volume":"7","author":"C Reitz","year":"2011","unstructured":"Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011;7(3):137\u201352.","journal-title":"Nat Rev Neurol."},{"key":"404_CR3","unstructured":"Bi\u00e9try F, Schur N, Pfeil A, et al. Helsana Arzneimittelreport. 2015. 1\u2013200."},{"issue":"2","key":"404_CR4","first-page":"136","volume":"72","author":"M Olfson","year":"2015","unstructured":"Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA. 2015;72(2):136\u201342.","journal-title":"JAMA."},{"key":"404_CR5","unstructured":"World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology. The Anatomical Therapeutic Chemical (ATC) and defined daily dosing (DDD) system. http:\/\/www.whocc.no\/atcddd\/ . Accessed 27 Jun 2014."},{"issue":"1","key":"404_CR6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1023\/A:1006456715525","volume":"46","author":"A Beurdeley-Thomas","year":"2000","unstructured":"Beurdeley-Thomas A, Miccoli L, Oudard S, et al. The peripheral benzodiazepine receptors: a review. J Neurooncol. 2000;46(1):45\u201356.","journal-title":"J Neurooncol."},{"issue":"6 Suppl 2","key":"404_CR7","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1097\/00004714-199912002-00002","volume":"19","author":"HJ Moller","year":"1999","unstructured":"Moller HJ. Effectiveness and safety of benzodiazepines. J Clin Psychopharmacol. 1999;19(6 Suppl 2):2S\u201311S.","journal-title":"J Clin Psychopharmacol."},{"key":"404_CR8","doi-asserted-by":"crossref","unstructured":"Dold M, Li C, Tardy M, et al. Benzodiazepines for schizophrenia (review). In: Dold M, editor. Cochrane Database of Systematic Reviews. Chichester: Wiley; 2012.","DOI":"10.1002\/14651858.CD006391.pub2"},{"key":"404_CR9","unstructured":"Documed AG. Compendium. http:\/\/www.documed.ch . Accessed 3 Feb 2016."},{"issue":"4","key":"404_CR10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0376-8716(84)90001-2","volume":"13","author":"AW Chan","year":"1984","unstructured":"Chan AW. Effects of combined alcohol and benzodiazepine: a review. Drug Alcohol Depend. 1984;13(4):315\u201341.","journal-title":"Drug Alcohol Depend."},{"issue":"1\u20132","key":"404_CR11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.drugalcdep.2012.07.004","volume":"125","author":"JD Jones","year":"2012","unstructured":"Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012;125(1\u20132):8\u201318.","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"404_CR12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00003495-198325040-00003","volume":"25","author":"RT Owen","year":"1983","unstructured":"Owen RT, Tyrer P. Benzodiazepine dependence: a review of the evidence. Drugs. 1983;25(4):385\u201398.","journal-title":"Drugs."},{"key":"404_CR13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0447.1998.tb05973.x","volume":"393","author":"E Schweizer","year":"1998","unstructured":"Schweizer E, Rickels K. Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiatr Scand Suppl. 1998;393:95\u2013101.","journal-title":"Acta Psychiatr Scand Suppl."},{"key":"404_CR14","unstructured":"Holt S, Schmiedl S, Th\u00fcrmann PA. PRISCUS-Liste potenziell inad\u00e4quater Medikation f\u00fcr \u00e4ltere Menschen. 2011."},{"key":"404_CR15","unstructured":"American Geriatric Society. AGS Beers criteria for potentially inappropriate medication use in older adults. Am Geriatr Soc; 2012."},{"issue":"1","key":"404_CR16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/CCM.0b013e318192fcf9","volume":"37","author":"M Pisani","year":"2009","unstructured":"Pisani M, Murphey T, Araujo KLB, et al. Benzodiazepine and opoid use and the duration of ICU delirium in an older population. Crit Care Med. 2009;37(1):177\u201383.","journal-title":"Crit Care Med."},{"issue":"1","key":"404_CR17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/1381612023396654","volume":"8","author":"SE Buffett-Jerrott","year":"2002","unstructured":"Buffett-Jerrott SE, Stewart SH. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des. 2002;8(1):45\u201358.","journal-title":"Curr Pharm Des."},{"issue":"2","key":"404_CR18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/11598560-000000000-00000","volume":"29","author":"C Parsons","year":"2012","unstructured":"Parsons C, Johnston S, Mathie E, et al. Potentially inappropriate prescribing in older people with dementia in care homes: a retrospective analysis. Drugs Aging. 2012;29(2):143\u201355.","journal-title":"Drugs Aging."},{"issue":"1","key":"404_CR19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.euroneuro.2013.09.003","volume":"24","author":"A Gallini","year":"2014","unstructured":"Gallini A, Andrieu S, Donohue JM, et al. Trends in use of antipsychotics in elderly patients with dementia: impact of national safety warnings. Eur Neuropsychopharmacol. 2014;24(1):95\u2013104.","journal-title":"Eur Neuropsychopharmacol."},{"issue":"7","key":"404_CR20","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/JGP.0b013e3181a65210","volume":"17","author":"C-S Wu","year":"2009","unstructured":"Wu C-S, Wang S-C, Chang I-S, Lin K-M. The association between dementia and long-term use of benzodiazepine in the elderly: nested case-control study using claims data. Am J Geriatr Psychiatry. 2009;17(7):614\u201320.","journal-title":"Am J Geriatr Psychiatry."},{"issue":"11","key":"404_CR21","doi-asserted-by":"crossref","first-page":"e49113","DOI":"10.1371\/journal.pone.0049113","volume":"7","author":"PL Chen","year":"2012","unstructured":"Chen PL, Lee WJ, Sun WZ, et al. Risk of dementia in patients with insomnia and long-term use of hypnotics: a population-based retrospective cohort study. PLoS One. 2012;7(11):e49113.","journal-title":"PLoS One."},{"issue":"2","key":"404_CR22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/JGP.0b013e3181e049ca","volume":"19","author":"CS Wu","year":"2011","unstructured":"Wu CS, Ting TT, Wang SC, et al. Effect of benzodiazepine discontinuation on dementia risk. Am J Geriatr Psychiatry. 2011;19(2):151\u20139.","journal-title":"Am J Geriatr Psychiatry."},{"issue":"3","key":"404_CR23","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0895-4356(01)00453-X","volume":"55","author":"R Lagnaoui","year":"2002","unstructured":"Lagnaoui R, Begaud B, Moore N, et al. Benzodiazepine use and risk of dementia: a nested case-control study. J Clin Epidemiol. 2002;55(3):314\u20138.","journal-title":"J Clin Epidemiol."},{"key":"404_CR24","doi-asserted-by":"crossref","first-page":"e6231","DOI":"10.1136\/bmj.e6231","volume":"345","author":"S Billioti de Gage","year":"2012","unstructured":"Billioti de Gage S, Begaud B, Bazin F, et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ. 2012;345:e6231.","journal-title":"BMJ."},{"key":"404_CR25","doi-asserted-by":"crossref","first-page":"g5205","DOI":"10.1136\/bmj.g5205","volume":"349","author":"SB Gage de","year":"2014","unstructured":"de Gage SB, Moride Y, Ducruet T, et al. Benzodiazepine use and risk of Alzheimer\u2019s disease: case-control study. BMJ. 2014;349:g5205.","journal-title":"BMJ."},{"issue":"10","key":"404_CR26","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/jech-2011-200314","volume":"66","author":"J Gallacher","year":"2012","unstructured":"Gallacher J, Elwood P, Pickering J, et al. Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS). J Epidemiol Commun Health. 2012;66(10):869\u201373.","journal-title":"J Epidemiol Commun Health."},{"issue":"10","key":"404_CR27","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s40264-015-0319-3","volume":"38","author":"P Imfeld","year":"2015","unstructured":"Imfeld P, Bodmer M, Jick SS, Meier CR. Benzodiazepine use is not associated with an increased risk of Alzheimer\u2019s disease or vascular dementia: case-control analysis. Drug Saf. 2015;38(10):909\u201319.","journal-title":"Drug Saf."},{"key":"404_CR28","doi-asserted-by":"crossref","first-page":"i90","DOI":"10.1136\/bmj.i90","volume":"352","author":"SL Gray","year":"2016","unstructured":"Gray SL, Dublin S, Yu O, et al. Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. BMJ. 2016;352:i90.","journal-title":"BMJ."},{"issue":"5","key":"404_CR29","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ana.21509","volume":"64","author":"H Amieva","year":"2008","unstructured":"Amieva H, Le Goff M, Millet X, et al. Prodromal Alzheimer\u2019s disease: successive emergence of the clinical symptoms. Ann Neurol. 2008;64(5):492\u20138.","journal-title":"Ann Neurol."},{"issue":"3","key":"404_CR30","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/YCO.0000000000000050","volume":"27","author":"F Stella","year":"2014","unstructured":"Stella F, Radanovic M, Balthazar MLF, et al. Neuropsychiatric symptoms in the prodromal stages of dementia. Curr Opin Psychiatry. 2014;27(3):230\u20135.","journal-title":"Curr Opin Psychiatry."},{"issue":"3","key":"404_CR31","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1001\/jamaneurol.2013.603","volume":"70","author":"E Richard","year":"2013","unstructured":"Richard E, Reitz C, Honig LH, et al. Late-life depression, mild cognitive impairment, and dementia. JAMA Neurol. 2013;70(3):383.","journal-title":"JAMA Neurol."},{"issue":"2","key":"404_CR32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0002-9343(80)90363-0","volume":"68","author":"RI Horwitz","year":"1980","unstructured":"Horwitz RI, Feinstein AR. The problem of \u201cprotopathic bias\u201d in case-control studies. Am J Med. 1980;68(2):255\u20138.","journal-title":"Am J Med."},{"issue":"8","key":"404_CR33","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1176\/ps.62.8.pss6208_0908","volume":"62","author":"CS Wu","year":"2011","unstructured":"Wu CS, Lin YJ, Liu SK. Benzodiazepine use among patients with schizophrenia in Taiwan: a nationwide population-based survey. Psychiatr Serv. 2011;62(8):908\u201314.","journal-title":"Psychiatr Serv."},{"key":"404_CR34","unstructured":"Helsana Gruppe. http:\/\/www.helsana.ch\/ . Accessed 31 Aug 2016."},{"key":"404_CR35","unstructured":"Bi\u00e9try F, Pitzurra R, Schwenkglenks M, Meier C. Helsana-Arzneimittelreport. 2014. 1\u2013200."},{"issue":"10","key":"404_CR36","doi-asserted-by":"crossref","first-page":"e0140874","DOI":"10.1371\/journal.pone.0140874","volume":"10","author":"T Mehra","year":"2015","unstructured":"Mehra T, M\u00fcller CTB, Volbracht J, et al. Predictors of high profit and high deficit outliers under SwissDRG of a tertiary care center. PLoS One. 2015;10(10):e0140874.","journal-title":"PLoS One."},{"key":"404_CR37","volume-title":"Diagnosis-Related Groups in Europe: moving towards transparency, efficiency","year":"2011","unstructured":"Busse R, Geissler A, Quentin W, Wiley M, editors. Diagnosis-Related Groups in Europe: moving towards transparency, efficiency. 1st ed. Maidenhead: McGraw-Hill, Open University Press; 2011.","edition":"1"},{"key":"404_CR38","unstructured":"SwissDRG. Abrechnungsversion Swiss Diagnosis-Related Groups. Vol. 1. http:\/\/www.swissdrg.org . Accessed 19 Dec 2016."},{"issue":"24","key":"404_CR39","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","volume":"351","author":"M Emre","year":"2004","unstructured":"Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson\u2019s disease. N Engl J Med. 2004;351(24):2509\u201318.","journal-title":"N Engl J Med."},{"issue":"3","key":"404_CR40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1474-4422(15)00389-0","volume":"15","author":"EJ Henderson","year":"2016","unstructured":"Henderson EJ, Lord SR, Brodie MA, et al. Rivastigmine for gait stability in patients with Parkinson\u2019s disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(3):249\u201358.","journal-title":"Lancet Neurol."},{"key":"404_CR41","unstructured":"Schweizerische Parkinsonvereinigung. Parkinson Schweiz. http:\/\/www.parkinson.ch . Accessed 12 Oct 2016"},{"issue":"2","key":"404_CR42","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/jnp.12067","volume":"10","author":"S Garc\u00eda-Herranz","year":"2016","unstructured":"Garc\u00eda-Herranz S, D\u00edaz-Mardomingo MC, Peraita H. Neuropsychological predictors of conversion to probable Alzheimer disease in elderly with mild cognitive impairment. J Neuropsychol. 2016;10(2):239\u201355.","journal-title":"J Neuropsychol."},{"issue":"S1","key":"404_CR43","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1017\/cjn.2016.2","volume":"43","author":"DB Hogan","year":"2016","unstructured":"Hogan DB, Fiest KM, Roberts JI, et al. The prevalence and incidence of dementia with Lewy bodies: a systematic review. Can J Neurol Sci. 2016;43(S1):S83\u201395.","journal-title":"Can J Neurol Sci."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0404-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-016-0404-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0404-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T03:54:50Z","timestamp":1498362890000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-016-0404-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,11]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["404"],"URL":"https:\/\/doi.org\/10.1007\/s40263-016-0404-x","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,11]]}}}